JWJared M. Whitson

Jared M. Whitson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jared M. Whitson has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Factors associated with downgrading in patients with high grade prostate cancer

    by Jared M. Whitson, Sima P. Porten, Janet E. Cowan, Jeff P. Simko, Matthew R. Cooperberg, Peter R. Carroll


  • The Future of Active Surveillance

    by Sima P. Porten, Jared M. Whitson, Peter R. Carroll

  • Lymphadenectomy Improves Survival of Patients With Renal Cell Carcinoma and Nodal Metastases

    by Jared M. Whitson, Catherine R. Harris, Adam C. Reese, Maxwell V. Meng

    In a population based cohort we determined whether an increase in the number of lymph nodes removed is associated with improved disease specific survival of patients with renal cell carcinoma treated with nephrectomy. Patients in the Surveillance, Epidemiology and End Results database with renal cell carcinoma and no evidence of distant metastases were identified. Those patients included in the study underwent radical or partial nephrectomy with lymphadenectomy. Cox regression analyses were performed to identify factors associated with disease specific survival including an interaction between lymph node status and the number of lymph nodes removed. Between 1988 and 2006, 9,586 patients with renal cell carcinoma met the study inclusion criteria. Median followup was 3.5 years (range 1.4 to 6.8). Of the patients 2,382 (25%) died of renal cell carcinoma, including 1,646 (20%) with lymph node negative disease and 736 (58%) with lymph node positive disease. There was no effect on disease specific survival with increasing the extent of lymphadenectomy in patients with negative lymph nodes (HR 1.0, 95% CI 0.9-1.1, p = 0.93). However, patients with positive lymph nodes had increased disease specific survival with extent of lymphadenectomy (HR 0.8 per 10 lymph nodes removed, 95% CI 0.7-1.0, p = 0.04). An increase of 10 lymph nodes in a patient with 1 positive lymph node was associated with a 10% absolute increase in disease specific survival at 5 years (p = 0.004). This study shows an association between increased lymph node yield and improved disease specific survival of patients with lymph node positive nonmetastatic renal cell carcinoma who underwent lymphadenectomy. Patients at high risk for nodal disease should be considered for regional or extended lymphadenectomy. Clinical variables to predict risk and validation of dissection templates are important areas for future research.


  • The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients on Active Surveillance for Prostate Cancer

    by Jared M. Whitson, Sima P. Porten, Joan F. Hilton, Janet E. Cowan, Nannette Perez, Matthew R. Cooperberg, Kirsten L. Greene, Maxwell V. Meng, Jeff P. Simko, Katsuto Shinohara, et al.

    We assessed whether an association exists between a change in prostate specific antigen and biopsy progression in men on active surveillance. A cohort of patients undergoing active surveillance for prostate cancer was identified from the urological oncology database at our institution. Multivariate logistic regression was performed to determine whether prostate specific antigen velocity, defined as the change in ln(prostate specific antigen) per year, is associated with biopsy progression, defined as a Gleason upgrade or volume progression on repeat biopsy within 24 months of diagnosis. A total of 241 men with a mean ± SD age of 61 ± 7 years and mean prostate specific antigen 4.9 ± 2.2 ng/ml met study inclusion criteria. Median time to repeat biopsy was 10 months (IQR 6-13). Biopsy progression developed in 55 men (23%), including a Gleason score upgrade in 46 (19%), greater than 33% positive cores in 11 (5%) and greater than 50% maximum single core positive in 12 (5%). The median prostate specific antigen ratio per year was 1.0 (IQR 0.95-1.03), although 1 man had a ratio of greater than 1.26 (doubled over 3 years) and 7 had a ratio of less than 1/1.26 (halved over 3 years). On multivariate analysis prostate specific antigen doubling within 3 years was associated with a 1.4-fold increase in the odds of biopsy progression (OR 1.4, 95% CI 0.6-3.4, p = 0.46). There is little change in prostate specific antigen during the first 24 months of surveillance in men with well staged, low risk prostate cancer. We believe that these findings highlight the importance of repeat biopsy during surveillance.


  • Reply

    by Glen Yang, Jared M. Whitson, Benjamin N. Breyer, Badrinath R. Konety, Peter R. Carroll

  • Reducing overtreatment: active surveillance in low-risk disease

    by Jared M. Whitson, Sima P. Porten, Peter R. Carroll


  • Open Access

    Factors associated with surgery in patients with renal cell carcinoma and venous tumor thrombus

    by Jared M. Whitson, Adam C. Reese, Maxwell V. Meng

    Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? This is the first published report which is an in‐depth analysis of factors associated with surgery versus non‐operative management in patients with renal cell carcinoma and venous tumour thrombus. OBJECTIVE: • Venous tumour thrombus is common in patients with renal cell carcinoma (RCC). Although surgical morbidity has decreased with time, nephrectomy with caval thrombectomy remains a high‐risk procedure and may not be performed in all patients with this condition. Little is known about the factors influencing the decision to pursue surgery versus conservative management in patients with RCC and venous tumour thrombus. MATERIALS AND METHODS: • The Surveillance, Epidemiology, and End Results database was used to identify study patients with RCC and venous tumour thrombus. • Multiple clinical, pathological and sociodemographic variables were assessed. • Univariable and multivariable logistic regression analysis was performed to identify factors associated with surgery. RESULTS: • We identified 24 396 patients with RCC, of which 2265 (9.3%) had venous tumour thrombus. • Distant metastases (odds ratio [OR] 0.1, 95% CI 0.0–0.1), clinical stage T3c (OR 0.3, 95% CI 0.2–0.6), lymph node involvement (OR 0.4, 95% CI 0.2–0.6), being single (OR 0.4, 95% CI 0.3–0.7), and the age categories 61–70 years (OR 0.4, 95% CI 0.2–0.8, P = 0.01), 71–80 years (OR 0.2, 95% CI 0.1–0.3, P < 0.001), and ≥80 years (OR 0.1, 95% CI 0.0–0.1, P < 0.001) were significantly associated with non‐surgical management. CONCLUSIONS: • In this population‐based study, over 80% of patients with RCC and venous tumour thrombus underwent surgical management. • Although age and TNM stage were strongly associated with the decision to undergo surgery, marital status was also associated with treatment choice. • It is unclear whether marital status affects oncological outcomes or complication rates so the reasons behind this association deserve further investigation.


  • Open Access

    Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer

    by Jared M. Whitson, Anna B. Berry, Peter R. Carroll, Badrinath R. Konety

    Purpose: In this study, we investigated the ability of UroVysion™ to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysion™ analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysion™ test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysion™ of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysion™ testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysion™ following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia


  • A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high‐risk superficial bladder tumours undergoing intravesical therapy

    by Jared Whitson, Anna Berry, Peter Carroll, Badrinath Konety

    OBJECTIVE: To determine whether a multicolour fluorescence in situ hybridization test (UroVysion TM , Abbott Molecular Inc., Des Plaines, IL, USA) in patients with high‐risk superficial bladder tumours maintains its predictive ability in a multivariate model for recurrence and progression, incorporating clinical and pathological predictors of outcome. PATIENTS AND METHODS: The charts of patients with superficial bladder cancer treated with induction or maintenance intravesical therapy (IVT) were reviewed retrospectively. UroVysion testing was used at the beginning and end of each IVT cycle, and cytology and cystoscopy 6 weeks after completing each cycle. Kaplan‐Meier actuarial survival was analysed, stratified by the UroVysion result after IVT. Univariate and multivariate Cox regression analyses were used to identify significant predictors of recurrence. RESULTS: In all, 42 patients had induction IVT with bacille Calmette‐Guérin (BCG), BCG + interferon, or mitomycin. The median follow‐up was 21 months. Recurrent disease was detected in 18 patients. In a univariate analysis, chronic renal insufficiency (hazard ratio 12.1, P = 0.03), positive cytology after IVT (2.7, P = 0.05), and a positive UroVysion test after IVT (8.3, P < 0.01) were predictive of failure. In the multivariate analysis, high grade disease (5.3, P = 0.05), a risk score of >6 (4.7, P = 0.02) and a positive UroVysion test after IVT (6.7, P < 0.01) were significant predictors of recurrence. CONCLUSION: In patients with high‐risk superficial bladder tumours undergoing IVT, a positive UroVysion test after treatment is highly predictive of recurrence, even in a multivariate model. Additional adjuvant therapy might be necessary in these patients to improve the outcome.